Rentschler

Senta Brandt and Gerrick Rodrigues appointed to Global Leadership Positions at Rentschler Biopharma

Retrieved on: 
Tuesday, February 6, 2024
Growth, Knowledge, Senior, CDMO, CSO, Transformation, Rentschler, Workforce, Management

Gerrick Rodrigues has been promoted to Global Head of IT, effective February 5, 2024, and is based at the Milford site.

Key Points: 
  • Gerrick Rodrigues has been promoted to Global Head of IT, effective February 5, 2024, and is based at the Milford site.
  • With their new appointments, Senta Brandt and Gerrick Rodrigues are joining the Global Leadership Team and will apply their expertise to drive excellence across the company.
  • We at Rentschler wish them all the best in their future endeavors.”
    Senta Brandt, Head of Transformation at Rentschler Biopharma, commented: “I am honored to take on the global responsibility for Transformation.
  • Gerrick Rodrigues, Global Head of IT at Rentschler Biopharma, noted: “I am excited about my new role and for the opportunity to lead this important area of our business.

EQS-News: Senta Brandt and Gerrick Rodrigues appointed to Global Leadership Positions at Rentschler Biopharma

Retrieved on: 
Tuesday, February 6, 2024
Growth, Knowledge, Senior, CDMO, CSO, Transformation, Rentschler, Workforce, Management

Gerrick Rodrigues has been promoted to Global Head of IT, effective February 5, 2024, and is based at the Milford site.

Key Points: 
  • Gerrick Rodrigues has been promoted to Global Head of IT, effective February 5, 2024, and is based at the Milford site.
  • With their new appointments, Senta Brandt and Gerrick Rodrigues are joining the Global Leadership Team and will apply their expertise to drive excellence across the company.
  • Gerrick Rodrigues, Global Head of IT at Rentschler Biopharma, noted: “I am excited about my new role and for the opportunity to lead this important area of our business.
  • The company announced the first major project with a long-standing client of Rentschler Biopharma in Germany in December 2023.

Atamyo Therapeutics Announces participation in Conferences and Key Scientific Communications on its LGMD programs

Retrieved on: 
Friday, September 29, 2023
Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Genetics, Clinical Trials, Muscular dystrophy, Natural history, International, Gene, C2, Rentschler, Part, ESGCT, Facial muscles, Neuromuscular disease, Diplomatic mission, Circulatory system, Rigshospitalet, Cell, Public, Oral, European Society of Clinical Microbiology and Infectious Diseases, Therapy, Conference, Pharmaceutical industry, Oyster farming, Nightclub, Rare-earth element, MD

Atamyo Therapeutics , a biotechnology company focused on the development of new-generation gene therapies targeting neuromuscular disease, today announced its participation to forthcoming conferences and scientific communications on its programs targeting limb-girdle muscular dystrophies (LGMDs).

Key Points: 
  • Atamyo Therapeutics , a biotechnology company focused on the development of new-generation gene therapies targeting neuromuscular disease, today announced its participation to forthcoming conferences and scientific communications on its programs targeting limb-girdle muscular dystrophies (LGMDs).
  • Stephane Degove, Atamyo CEO, will provide a corporate overview at two forthcoming conferences in October:
    Chardan's 7th Annual Genetic Medicines Conference, held in New York City:
    - Presentation on October 2, at 10:30 AM, in the Embassy room
    Cell & Gene Meeting on the Mesa, held in Carlsbad, CA, on October 10-12, 2023:
    - Presentation on October 10, at 5:15pm, at the Rentschler ATMP Ballroom
    Two upcoming communications at the 28th Annual Congress of the World Muscle Society (3-7 October 2023 in Charleston, SC)
    • Oral Presentation by A. Brureau (Genethon), at Ballroom C2 on October 4, 2023 from 18h15 to 18h45
    • Poster Board Number 282 at Ballroom C, on October 4, 2023, 17h15-18h15
    Natural history of limb girdle muscular dystrophy R9: one-year follow-up of a European cohort
    • Oral Presentation by J. Vissing (Copenhagen Neuromuscular Center, Rigshospitale) at Ballroom C2 on October 4, 2023 from 18h15 to 18h45
    • Poster Board Number 283 at Ballroom C, on October 4, 2023, 17h15-18h15
    Two communications describing Atamyo’s LGMD programs will be presented at the 30th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT) that will take place on October 24-27, 2023 in Brussel (Belgium):
    • Oral presentation by Nicolai Preisler, MD, Rigshospitalet, Copenhagen, during the Cardiovascular and muscular diseases session, on Friday October 27, 11h30-13h00 – Le BEL, Tour & Taxis
    Oral presentation on Atamyo’s LGMD-R9 program at the 2023 International Limb-Girdle Muscular Dystrophy Conference (28-29 October 2023, Washington DC)
    • Oral presentation by John Vissing, MD, Rigshospitalet, Copenhagen, during the Clinical Trials Updates (Part 1) Session, on October 29, 11h00am-12h10pm – Constitution Ballroom, Grand Hyatt

EQS-News: Rentschler Biopharma’s ATMP facility in UK receives MHRA approval

Retrieved on: 
Saturday, September 16, 2023
Gene, CMC, Quality of life, ATMP, Rentschler, Medicine, AAV, CDMO, CGMP, Patient, Cell, Medicines and Healthcare products Regulatory Agency, Health, MHRA, Pharmaceutical industry

Rentschler Biopharma’s ATMP facility in Stevenage, UK, receives MHRA approval

Key Points: 
  • Rentschler Biopharma’s ATMP facility in Stevenage, UK, receives MHRA approval
    Stevenage, UK and Laupheim, Germany, September 13, 2023 – Rentschler Biopharma SE, a leading global contract development and manufacturing organization (CDMO) for biopharmaceuticals, including advanced therapy medicinal products (ATMPs), today announced that it has received the cGMP Manufacturing Compliance Certificate, following the successful inspection by the UK Medicines & Healthcare Products Regulatory Agency (MHRA) at its UK site.
  • The ATMP business was announced in early 2021 and the facility is located in the Cell and Gene Therapy Catapult’s Manufacturing Innovation Centre in Stevenage.
  • Dr. Robert Panting, General Manager of Rentschler Biopharma’s ATMP business, said: “MHRA’s approval marks a major milestone for Rentschler Biopharma, and we are excited to offer our services from process and analytical development through cGMP manufacturing.
  • We are thus continuing the Rentschler tradition of offering a truly client-centric approach with the ultimate goal of helping patients.

Rentschler Biopharma’s ATMP facility in Stevenage, UK, receives MHRA approval

Retrieved on: 
Wednesday, September 13, 2023
Gene, CMC, Quality of life, ATMP, Rentschler, Medicine, AAV, CDMO, CGMP, Patient, Cell, Medicines and Healthcare products Regulatory Agency, Health, MHRA, Pharmaceutical industry

The ATMP business was announced in early 2021 and the facility is located in the Cell and Gene Therapy Catapult’s Manufacturing Innovation Centre in Stevenage.

Key Points: 
  • The ATMP business was announced in early 2021 and the facility is located in the Cell and Gene Therapy Catapult’s Manufacturing Innovation Centre in Stevenage.
  • Dr. Robert Panting, General Manager of Rentschler Biopharma’s ATMP business, said: “MHRA’s approval marks a major milestone for Rentschler Biopharma, and we are excited to offer our services from process and analytical development through cGMP manufacturing.
  • We are thus continuing the Rentschler tradition of offering a truly client-centric approach with the ultimate goal of helping patients.
  • It is gratifying to achieve this important milestone of MHRA approval, bringing us closer to reaching our objective of supporting clients already from the earliest stages of CMC development.

EQS-News: Rentschler Biopharma’s service excellence recognized with CDMO Leadership Awards and Champion status

Retrieved on: 
Monday, March 20, 2023
Business development, Partnership, Senior, ISR, Rentschler, Research, Industry Standard, Compatibility, CDMO, Publication, Patient, Conference, Republican Conference Chair, Fine chemical

Champion status in the Compatibility category highlights outstanding cultural fit, project management and reputation

Key Points: 
  • Champion status in the Compatibility category highlights outstanding cultural fit, project management and reputation
    Laupheim, Germany, March 20, 2023 – Rentschler Biopharma SE, a leading global contract development and manufacturing organization (CDMO) for biopharmaceuticals, is proud to announce that the company has been awarded CDMO Leadership Awards in the categories of Service, Reliability, Capabilities and Compatibility.
  • In addition, Rentschler was recognized as a CDMO Leadership Award Champion in the Compatibility category.
  • The awards are based on client feedback and honor Rentschler’s overall service performance for big and small pharma combined.
  • The CDMO Leadership Awards Ceremony and Reception will be held in New York City on March 22, 2023.

Rentschler Biopharma’s service excellence recognized with CDMO Leadership Awards and Champion status

Retrieved on: 
Monday, March 20, 2023
Business development, Partnership, Senior, ISR, Rentschler, Research, Industry Standard, Compatibility, CDMO, Publication, Patient, Conference, Republican Conference Chair, Fine chemical

In addition, Rentschler was recognized as a CDMO Leadership Award Champion in the Compatibility category.

Key Points: 
  • In addition, Rentschler was recognized as a CDMO Leadership Award Champion in the Compatibility category.
  • The awards are based on client feedback and honor Rentschler’s overall service performance for big and small pharma combined.
  • For the 2023 CDMO Leadership Awards, Life Science Leader and Outsourced Pharma, presenters of the awards, once again teamed up with Industry Standard Research (ISR) to determine the award recipients.
  • The CDMO Leadership Awards Ceremony and Reception will be held in New York City on March 22, 2023.

Dr Frank Mathias to join Oxford Biomedica as new CEO on 27 March 2023

Retrieved on: 
Monday, February 20, 2023
LSE, Stuart, Oxford Biomedica, Stuart Henderson, Rentschler, Patient, Interim, Senior, OXB, Growth, Chair, CDMO, Management

Dr Mathias brings a wealth of experience in innovation, contract development and manufacturing to Oxford Biomedica

Key Points: 
  • Dr Mathias brings a wealth of experience in innovation, contract development and manufacturing to Oxford Biomedica
    Oxford, UK – 20 February 2023: Oxford, UK – Oxford Biomedica (LSE:OXB), a leading gene and cell therapy group, today announces that Dr Frank Mathias will officially join Oxford Biomedica as Chief Executive Officer (CEO) and Board member on Monday, 27th March 2023.
  • Dr Frank Mathias joins Oxford Biomedica from Rentschler Biopharma SE (“Rentschler”) where he has been CEO since 2016.
  • Dr Roch Doliveux, Chair and Interim CEO of Oxford Biomedica, said: “We are extremely excited about the imminent arrival of Frank as our new CEO.
  • Oxford Biomedica has a clear vision for the future, and I believe it has great potential to become the leader in the viral vector CDMO market.

EQS-News: Rentschler Biopharma appoints Christiane Bardroff as Chief Operating Officer and Member of the Executive Board

Retrieved on: 
Sunday, November 27, 2022
Rentschler, Christiane, Environment, Engineering, Chemical engineering, Zhejiang University of Science and Technology, Trust, RTÉ Executive Board, Biotechnology, Creativity, Senior, Supervisory board, Automation, SVP, Commercial, Roche, Applied science, CDMO, Management, Fine chemical

Prof. Dr. Nikolaus F. Rentschler, Chairman of the Supervisory Board of Rentschler Biopharma SE, said: I am very pleased that Christiane Bardroff will take on the important role of Chief Operating Officer.

Key Points: 
  • Prof. Dr. Nikolaus F. Rentschler, Chairman of the Supervisory Board of Rentschler Biopharma SE, said: I am very pleased that Christiane Bardroff will take on the important role of Chief Operating Officer.
  • Christiane is an experienced manager and an outstanding leader who has already achieved a lot since joining Rentschler Biopharma earlier this year.
  • Rentschler Biopharma is a family-owned company with about 1,100 employees, headquartered in Laupheim, Germany, with a second site in Milford, MA, USA.
  • In Stevenage, UK, Rentschler Biopharma has launched a company dedicated to cell and gene therapies, Rentschler ATMP Ltd.

Oxford Biomedica Appoints Dr Frank Mathias as Chief Executive Officer

Retrieved on: 
Tuesday, November 22, 2022
Rentschler, Growth, Hoechst AG, Chair, OXB, BioNTech, European Union (Withdrawal) Act 2018, Amgen, RNA transfection, Oxford BioMedica, Interim, LSE, Oxford, LR, CDMO, Acquisition, Management, Pharmaceutical industry, Laboratoires Servier, EU

Oxford, UK 22 November 2022:Oxford Biomedica plc (LSE:OXB) (Oxford Biomedica or the Company), a leading gene and cell therapy group, today announces the appointment of Dr Frank Mathias as Chief Executive Officer (CEO) and Board Director, effective March 2023.

Key Points: 
  • Oxford, UK 22 November 2022:Oxford Biomedica plc (LSE:OXB) (Oxford Biomedica or the Company), a leading gene and cell therapy group, today announces the appointment of Dr Frank Mathias as Chief Executive Officer (CEO) and Board Director, effective March 2023.
  • Dr Mathias brings world-class innovation and contract development and manufacturing experience to Oxford Biomedica.
  • Commenting on the appointment, Dr Roch Doliveux, Chair and Interim CEO of Oxford Biomedica, said: I, on behalf of the Board, am delighted to welcome Frank as CEO of Oxford Biomedica.
  • Dr Frank Mathias, incoming Chief Executive Officer, said: Oxford Biomedica is a world-leader in the innovative development and manufacture of viral vectors for life-saving cell and gene therapies, demonstrated by the ever-expanding customer base of now more than 20 programmes across all vector types.